Tobacco
Compare Stocks
4 / 10Stock Comparison
XXII vs CGC vs ACB vs TLRY
Revenue, margins, valuation, and 5-year total return — side by side.
Drug Manufacturers - Specialty & Generic
Drug Manufacturers - Specialty & Generic
Drug Manufacturers - Specialty & Generic
XXII vs CGC vs ACB vs TLRY — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||||
|---|---|---|---|---|
| Industry | Tobacco | Drug Manufacturers - Specialty & Generic | Drug Manufacturers - Specialty & Generic | Drug Manufacturers - Specialty & Generic |
| Market Cap | $119K | $122M | $195M | $660M |
| Revenue (TTM) | $19M | $294M | $361M | $1.17B |
| Net Income (TTM) | $-4M | $-327M | $41M | $-2.95B |
| Gross Margin | -15.2% | 22.8% | 62.7% | 28.0% |
| Operating Margin | -62.0% | -24.1% | 13.3% | -266.0% |
| Forward P/E | — | — | 164.2x | — |
| Total Debt | $4M | $348M | $104M | $451M |
| Cash & Equiv. | $7M | $114M | $184M | $304M |
XXII vs CGC vs ACB vs TLRY — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| 22nd Century Group,… (XXII) | 100 | 0.0 | -100.0% |
| Canopy Growth Corpo… (CGC) | 100 | 0.7 | -99.3% |
| Aurora Cannabis Inc. (ACB) | 100 | 2.4 | -97.6% |
| Tilray Brands, Inc. (TLRY) | 100 | 57.5 | -42.5% |
Price return only. Dividends and distributions are not included.
Quick Verdict: XXII vs CGC vs ACB vs TLRY
Each card shows where this stock fits in a portfolio — not just who wins on paper.
XXII carries the broadest edge in this set and is the clearest fit for income & stability.
- Dividend streak 0 yrs, beta 1.60, yield 100.0%
- 48.1% revenue growth vs CGC's -9.5%
- Beta 1.60 vs TLRY's 2.03
- 100.0% yield; the other 3 pay no meaningful dividend
CGC lags the leaders in this set but could rank higher in a more targeted comparison.
ACB is the #2 pick in this set and the best alternative if growth exposure and sleep-well-at-night is your priority.
- Rev growth 27.0%, EPS growth 102.2%, 3Y rev CAGR 15.8%
- Lower volatility, beta 1.81, Low D/E 17.2%, current ratio 4.31x
- Beta 1.81, current ratio 4.31x
- 11.2% margin vs TLRY's -252.6%
TLRY is the clearest fit if your priority is long-term compounding.
- -74.7% 10Y total return vs ACB's -92.0%
- +12.1% vs XXII's -99.8%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 48.1% revenue growth vs CGC's -9.5% | |
| Quality / Margins | 11.2% margin vs TLRY's -252.6% | |
| Stability / Safety | Beta 1.60 vs TLRY's 2.03 | |
| Dividends | 100.0% yield; the other 3 pay no meaningful dividend | |
| Momentum (1Y) | +12.1% vs XXII's -99.8% | |
| Efficiency (ROA) | 5.2% ROA vs TLRY's -100.6%, ROIC 0.7% vs -66.2% |
XXII vs CGC vs ACB vs TLRY — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
XXII vs CGC vs ACB vs TLRY — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
ACB leads in 2 of 6 categories
XXII leads 1 • TLRY leads 1 • CGC leads 0 • 1 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
ACB leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
TLRY is the larger business by revenue, generating $1.2B annually — 60.2x XXII's $19M. ACB is the more profitable business, keeping 11.2% of every revenue dollar as net income compared to TLRY's -2.5%. On growth, XXII holds the edge at +80.4% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||||
|---|---|---|---|---|
| RevenueTrailing 12 months | $19M | $294M | $361M | $1.2B |
| EBITDAEarnings before interest/tax | -$11M | -$32M | $71M | -$3.0B |
| Net IncomeAfter-tax profit | -$4M | -$327M | $41M | -$2.9B |
| Free Cash FlowCash after capex | -$8M | -$86M | -$31M | -$94M |
| Gross MarginGross profit ÷ Revenue | -15.2% | +22.8% | +62.7% | +28.0% |
| Operating MarginEBIT ÷ Revenue | -62.0% | -24.1% | +13.3% | -2.7% |
| Net MarginNet income ÷ Revenue | -20.5% | -111.0% | +11.2% | -2.5% |
| FCF MarginFCF ÷ Revenue | -40.8% | -29.3% | -8.7% | -8.1% |
| Rev. Growth (YoY)Latest quarter vs prior year | +80.4% | +20.9% | +6.8% | +3.0% |
| EPS Growth (YoY)Latest quarter vs prior year | +58.0% | +83.8% | -94.5% | +70.7% |
Valuation Metrics
XXII leads this category, winning 2 of 3 comparable metrics.
Valuation Metrics
| Metric | ||||
|---|---|---|---|---|
| Market CapShares × price | $118,791 | $122M | $195M | $660M |
| Enterprise ValueMkt cap + debt − cash | -$3M | $293M | $136M | $806M |
| Trailing P/EPrice ÷ TTM EPS | -0.01x | -0.28x | 164.21x | -0.17x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — |
| EV / EBITDAEnterprise value multiple | — | — | 6.73x | — |
| Price / SalesMarket cap ÷ Revenue | 0.01x | 0.62x | 0.77x | 0.59x |
| Price / BookPrice ÷ Book value/share | 0.01x | 0.34x | 0.43x | 0.25x |
| Price / FCFMarket cap ÷ FCF | — | — | — | — |
Profitability & Efficiency
ACB leads this category, winning 8 of 9 comparable metrics.
Profitability & Efficiency
ACB delivers a 7.2% return on equity — every $100 of shareholder capital generates $7 in annual profit, vs $-137 for TLRY. ACB carries lower financial leverage with a 0.17x debt-to-equity ratio, signaling a more conservative balance sheet compared to CGC's 0.72x. On the Piotroski fundamental quality scale (0–9), ACB scores 7/9 vs TLRY's 4/9, reflecting strong financial health.
| Metric | ||||
|---|---|---|---|---|
| ROE (TTM)Return on equity | -25.0% | -43.1% | +7.2% | -136.5% |
| ROA (TTM)Return on assets | -14.2% | -29.5% | +5.2% | -100.6% |
| ROICReturn on invested capital | -81.4% | -10.2% | +0.7% | -66.2% |
| ROCEReturn on capital employed | -72.6% | -12.4% | +0.7% | -78.1% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 5 | 7 | 4 |
| Debt / EquityFinancial leverage | 0.27x | 0.72x | 0.17x | 0.22x |
| Net DebtTotal debt minus cash | -$3M | $235M | -$80M | $147M |
| Cash & Equiv.Liquid assets | $7M | $114M | $184M | $304M |
| Total DebtShort + long-term debt | $4M | $348M | $104M | $451M |
| Interest CoverageEBIT ÷ Interest expense | -10.14x | -7.79x | 6.27x | -89.43x |
Total Returns (Dividends Reinvested)
TLRY leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in TLRY five years ago would be worth $3,498 today (with dividends reinvested), compared to $0 for XXII. Over the past 12 months, TLRY leads with a +1209.3% total return vs XXII's -99.8%. The 3-year compound annual growth rate (CAGR) favors TLRY at 26.7% vs XXII's -99.0% — a key indicator of consistent wealth creation.
| Metric | ||||
|---|---|---|---|---|
| YTD ReturnYear-to-date | -94.6% | -5.0% | -21.0% | -41.8% |
| 1-Year ReturnPast 12 months | -99.8% | -12.4% | -25.3% | +1209.3% |
| 3-Year ReturnCumulative with dividends | -100.0% | -91.4% | -47.2% | +103.6% |
| 5-Year ReturnCumulative with dividends | -100.0% | -99.6% | -96.1% | -65.0% |
| 10-Year ReturnCumulative with dividends | -100.0% | -94.3% | -92.0% | -74.7% |
| CAGR (3Y)Annualised 3-year return | -99.0% | -55.9% | -19.2% | +26.7% |
Risk & Volatility
Evenly matched — XXII and ACB each lead in 1 of 2 comparable metrics.
Risk & Volatility
XXII is the less volatile stock with a 1.60 beta — it tends to amplify market swings less than TLRY's 2.03 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ACB currently trades 51.4% from its 52-week high vs XXII's 0.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||||
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.60x | 1.90x | 1.81x | 2.03x |
| 52-Week HighHighest price in past year | $455.40 | $2.38 | $6.67 | $15.70 |
| 52-Week LowLowest price in past year | $0.67 | $0.84 | $3.07 | $0.35 |
| % of 52W HighCurrent price vs 52-week peak | +0.2% | +47.5% | +51.4% | +36.1% |
| RSI (14)Momentum oscillator 0–100 | 15.1 | 52.9 | 52.2 | 37.9 |
| Avg Volume (50D)Average daily shares traded | 1.4M | 10.4M | 979K | 4.7M |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: CGC as "Hold", ACB as "Hold", TLRY as "Hold". Consensus price targets imply 1180.5% upside for CGC (target: $14) vs 72.6% for ACB (target: $6). XXII is the only dividend payer here at 100.00% yield — a key consideration for income-focused portfolios.
| Metric | ||||
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Hold | Hold | Hold |
| Price TargetConsensus 12-month target | — | $14.47 | $5.92 | $10.00 |
| # AnalystsCovering analysts | — | 26 | 14 | 20 |
| Dividend YieldAnnual dividend ÷ price | +100.0% | — | — | — |
| Dividend StreakConsecutive years of raises | 0 | — | — | — |
| Dividend / ShareAnnual DPS | $25.42 | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | 0.0% | 0.0% |
ACB leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). XXII leads in 1 (Valuation Metrics). 1 tied.
XXII vs CGC vs ACB vs TLRY: Key Questions Answered
8 questions · data-driven answers · updated daily
01Is XXII or CGC or ACB or TLRY a better buy right now?
For growth investors, 22nd Century Group, Inc.
(XXII) is the stronger pick with 48. 1% revenue growth year-over-year, versus -9. 5% for Canopy Growth Corporation (CGC). Aurora Cannabis Inc. (ACB) offers the better valuation at 164. 2x trailing P/E, making it the more compelling value choice. Analysts rate Canopy Growth Corporation (CGC) a "Hold" — based on 26 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — XXII or CGC or ACB or TLRY?
Over the past 5 years, Tilray Brands, Inc.
(TLRY) delivered a total return of -65. 0%, compared to -100. 0% for 22nd Century Group, Inc. (XXII). Over 10 years, the gap is even starker: TLRY returned -74. 7% versus XXII's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — XXII or CGC or ACB or TLRY?
By beta (market sensitivity over 5 years), 22nd Century Group, Inc.
(XXII) is the lower-risk stock at 1. 60β versus Tilray Brands, Inc. 's 2. 03β — meaning TLRY is approximately 27% more volatile than XXII relative to the S&P 500. On balance sheet safety, Aurora Cannabis Inc. (ACB) carries a lower debt/equity ratio of 17% versus 72% for Canopy Growth Corporation — giving it more financial flexibility in a downturn.
04Which is growing faster — XXII or CGC or ACB or TLRY?
By revenue growth (latest reported year), 22nd Century Group, Inc.
(XXII) is pulling ahead at 48. 1% versus -9. 5% for Canopy Growth Corporation (CGC). On earnings-per-share growth, the picture is similar: Aurora Cannabis Inc. grew EPS 102. 2% year-over-year, compared to -651. 7% for Tilray Brands, Inc.. Over a 3-year CAGR, ACB leads at 15. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — XXII or CGC or ACB or TLRY?
Aurora Cannabis Inc.
(ACB) is the more profitable company, earning 0. 5% net margin versus -266. 3% for Tilray Brands, Inc. — meaning it keeps 0. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ACB leads at 1. 4% versus -277. 9% for TLRY. At the gross margin level — before operating expenses — ACB leads at 54. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — XXII or CGC or ACB or TLRY?
In this comparison, XXII (100.
0% yield) pays a dividend. CGC, ACB, TLRY do not pay a meaningful dividend and should not be held primarily for income.
07Is XXII or CGC or ACB or TLRY better for a retirement portfolio?
For long-horizon retirement investors, 22nd Century Group, Inc.
(XXII) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (100. 0% yield). Tilray Brands, Inc. (TLRY) carries a higher beta of 2. 03 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (XXII: -100. 0%, TLRY: -74. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between XXII and CGC and ACB and TLRY?
These companies operate in different sectors (XXII (Consumer Defensive) and CGC (Healthcare) and ACB (Healthcare) and TLRY (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: XXII is a small-cap high-growth stock; CGC is a small-cap quality compounder stock; ACB is a small-cap high-growth stock; TLRY is a small-cap quality compounder stock. XXII pays a dividend while CGC, ACB, TLRY do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
- Sector: Consumer Defensive
- Market Cap > $20B
- Revenue Growth > 40%
- Dividend Yield > 40.0%
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.